NCT03952065View on ClinicalTrials.gov

IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

January 1, 2029

Study Completion Date

January 1, 2035

Conditions
Head/Neck Neoplasm
Interventions
DRUG

PD1/PDL1/CTLA4 inhibitors

Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.

Trial Locations (1)

510260

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guanzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER